Combination of biologicals in indolent lymphoma: finally the end of chemotherapy era in indolent lymphoma?

Affiliations

Comment

Martin Dreyling. Leuk Lymphoma. 2008 Jan.

. 2008 Jan;49(1):8-9.

doi: 10.1080/10428190701861694.

¹ Medizinische Klinik III der Universität Münich-Grosshadern, Germany. martin.dreyling@med.uni-muenchen.de

No abstract available

Comment on

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.
Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C; Nordic Lymphoma Group. Kimby E, et al. Leuk Lymphoma. 2008 Jan;49(1):102-12. doi: 10.1080/10428190701704647. Leuk Lymphoma. 2008. PMID: 18203019 Clinical Trial.